CI-984, 17AA70, PD 132301-2 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
81先天性副腎皮質酵素欠損症2

81. 先天性副腎皮質酵素欠損症


臨床試験数 : 87 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-004878-34-FR
(EUCTR)
18/09/201824/04/2018A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal HyperplasiaA Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: Nevanimibe Hydrochloride
Product Code: ATR-101
INN or Proposed INN: Nevanimibe hydrochloride
Other descriptive name: CI-984, 17AA70, PD 132301-2
Millendo Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
24Phase 2France;Spain;Brazil;Israel
2EUCTR2017-004878-34-ES
(EUCTR)
01/08/201821/05/2018A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal HyperplasiaA Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia
MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: Nevanimibe Hydrochloride
Product Code: ATR-101
INN or Proposed INN: Nevanimibe hydrochloride
Other descriptive name: CI-984, 17AA70, PD 132301-2
Millendo Therapeutics US, Inc.NULLNot RecruitingFemale: yes
Male: yes
24Phase 2France;Brazil;Spain;Israel